We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$4.89B
$25.1M 1.02%
521,353
-65,647
-11% -$2.91M
MRK icon
27
Merck
MRK
$312B
$24.4M 0.99%
+203,000
New +$23.4M
ORGO icon
28
Organogenesis Holdings
ORGO
$345M
$23.9M 0.97%
10,085,951
+100,000
+1% +$346K
NTRA icon
29
Natera
NTRA
$38.3B
$23.8M 0.96%
119,000
+99,000
+495% +$21.3M
AXGN icon
30
Axogen
AXGN
$2.14B
$22.5M 0.91%
679,170
-527,685
-44% -$17.2M
PCVX icon
31
Vaxcyte
PCVX
$8.38B
$22.4M 0.91%
385,472
-223,486
-37% -$12.1M
ICLR icon
32
Icon
ICLR
$12.9B
$21.2M 0.86%
+192,000
New +$26.2M
PHVS icon
33
Pharvaris
PHVS
$2.41B
$19.8M 0.8%
702,052
– –
CERS icon
34
Cerus
CERS
$625M
$19.6M 0.79%
10,753,700
+6,753,700
+169% +$14.7M
TRVI icon
35
Trevi Therapeutics
TRVI
$2.58B
$19.3M 0.78%
1,620,000
+720,000
+80% +$8.06M
IKT icon
36
Inhibikase Therapeutics
IKT
$350M
$18.3M 0.74%
10,875,000
– –
CNTX icon
37
Context Therapeutics
CNTX
$57.9M
$18.2M 0.74%
+6,963,141
New +$16.3M
VIR icon
38
Vir Biotechnology
VIR
$1.59B
$17.9M 0.73%
+2,002,000
New +$16M
XENE icon
39
Xenon Pharmaceuticals
XENE
$6.45B
$17M 0.69%
+292,000
New +$13.5M
TVTX icon
40
Travere Therapeutics
TVTX
$5.26B
$16.2M 0.66%
+546,000
New +$16.3M
TNDM icon
41
Tandem Diabetes Care
TNDM
$1.21B
$15M 0.61%
+783,000
New +$17M
NRIX icon
42
Nurix Therapeutics
NRIX
$2.44B
$14.5M 0.59%
938,163
-281,231
-23% -$4.66M
URGN icon
43
UroGen Pharma
URGN
$2.13B
$13.1M 0.53%
727,000
+577,000
+385% +$11.6M
SION
44
Sionna Therapeutics
SION
$2.13B
$11.8M 0.48%
293,500
+25,000
+9% +$954K
CORT icon
45
Corcept Therapeutics
CORT
$10.3B
$11.5M 0.47%
+285,531
New +$10.7M
JBIO
46
Jade Biosciences
JBIO
$1.25B
$11.2M 0.45%
796,744
– –
VCYT icon
47
Veracyte
VCYT
$4.75B
$10.3M 0.42%
319,912
+309,912
+3,099% +$11.5M
IVVD icon
48
Invivyd
IVVD
$201M
$10M 0.41%
7,708,727
– –
CCCC icon
49
C4 Therapeutics
CCCC
$423M
$10M 0.41%
3,803,942
– –
KIDS icon
50
OrthoPediatrics
KIDS
$501M
$9.77M 0.4%
615,447
+90,000
+17% +$1.57M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.